There is increasing evidence that a relevant number of patients with hepatocellular carcinoma (HCC) exceeding the Milan criteria may benefit from liver transplantation (LT). We retrospectively analyzed the prognostic significance of [ 18 F]fludeoxyglucose ([ 18 F]FDG) positron emission tomography (PET) for identifying appropriate LT candidates with advanced HCC on clinical staging. Between 1995 and 2008, 111 patients with HCC were listed for LT. All underwent a pretransplant PET evaluation. LT was performed for 91 of these patients. The tumor recurrence rate after LT was 3.6% for patients with non-[ 18 F]FDG-avid (PET À ) tumors, but it was 54.3% for patients with [ 18 F]FDG-avid (PET þ ) tumors (P < 0.001). The 5-year recurrence-free survival rates were comparable for patients with tumors meeting the Milan criteria (86.2%) and patients with PET À HCC exceeding the Milan criteria (81%) at LT, but these rates were significantly higher than the rate for liver recipients with [ 18 F]FDG-avid advanced HCC (21%, P ¼ 0.002). In a multivariate analysis, negative PET findings (odds ratio ¼ 21.6, P < 0.001), an alpha-fetoprotein level <400 IU/mL (odds ratio ¼ 3.3, P ¼ 0.013), and a total tumor diameter <10 cm (odds ratio ¼ 3.0, P ¼ 0.022) were identified as pretransplant prognostic variables for recurrence-free survival. A PET þ status was assessed as the only independent clinical predictor of tumor-related patient dropout from the waiting list (hazard ratio ¼ 5.7, P ¼ 0.01). Patients with non-[ 18 F]FDG-avid HCC beyond the Milan criteria according to clinical staging may achieve excellent long-term recurrence-free survival after LT.
Our study suggests that antiviral treatment withdrawal carries the risk of severe disease progression in persistently viremic HCV-positive liver transplant patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.